Rituximab Monoclonal Antibody Injection from China
Rituximab is a genetically engineered chimeric monoclonal antibody targeting CD20 on B-cells, used for treating non-Hodgkin lymphoma and rheumatoid arthritis. It falls under HTS 3002.15.00.11 as an immunological product containing monoclonal antibodies, put up in measured doses for retail sale in pre-filled syringes or vials.
Duty Rate — China → United States
0%
Rate breakdown
9903.03.030%Articles the product of any country, as provided for in subdivision (aa)(ii) of U.S. note 2 to this subchapter
Import Tips
• Obtain FDA biologics license and ensure proper cold chain documentation (2-8°C) to avoid spoilage during import
• Include certificates of analysis verifying monoclonal antibody purity and biotech origin; declare as immunological product
• Avoid misclassification as general pharmaceuticals; common pitfall is insufficient proof of measured doses for retail